Abatacept+MTX, n=203 | Placebo+MTX, n=202 | Total, N=405 | |
Age (years) | 56.6 (12.47) | 54.8 (12.14) | 55.7 (12.32) |
Weight (kg) | 55.9 (11.23) | 56.0 (11.24) | 55.9 (11.22) |
Sex, female, n (%) | 165 (81.3) | 175 (86.6) | 340 (84.0) |
Duration of RA disease (months) | 21.4 (16.61) | 20.9 (16.38) | 21.2 (16.48) |
Duration of disease | |||
≤2 years | 133 (65.5) | 133 (65.8) | 266 (65.7) |
>2 to ≤5 years | 70 (34.5) | 69 (34.2) | 139 (34.3) |
>5 years | 0 | 0 | 0 |
Tender joints | 13.8 (8.94) | 13.9 (8.32) | 13.9 (8.63) |
Swollen joints | 13.0 (7.97) | 12.3 (6.84) | 12.7 (7.42) |
HAQ-DI* | 1.0 (0.70) | 0.9 (0.64) | 0.9 (0.67) |
Patient global assessment (mm) | 48.3 (26.16) | 47.9 (26.05) | 48.1 (26.07) |
Pain (mm) | 52.9 (24.82) | 52.7 (25.34) | 52.8 (25.05) |
Physician global assessment (mm) | 56.2 (19.25) | 56.6 (19.55) | 56.4 (19.38) |
CRP (mg/dL) | 1.7 (2.30) | 1.5 (2.19) | 1.6 (2.25) |
DAS28 (CRP) | 4.9 (1.04) | 4.7 (1.06) | 4.8 (1.05) |
DAS28 (CRP) category, n (%) | |||
<3.2 | 8 (3.9) | 13 (6.4) | 21 (5.2) |
3.2–5.1 | 108 (53.2) | 122 (60.4) | 230 (56.8) |
>5.1 | 87 (42.9) | 67 (33.2) | 154 (38.0) |
TSS | 11.3 (19.87) | 10.7 (14.37) | 11.0 (17.33) |
Erosion score | 5.4 (10.07) | 5.6 (7.47) | 5.5 (8.86) |
JSN score | 5.9 (10.67) | 5.1 (7.73) | 5.5 (9.32) |
MTX weekly dose (mg) | 9.6 (2.79) | 9.6 (2.82) | 9.6 (2.81) |
MTX weekly dose category, n (%) | |||
≤8 mg | 101 (49.8) | 96 (47.5) | 197 (48.6) |
>8 mg | 102 (50.2) | 106 (52.5) | 208 (51.4) |
Use of oral steroid at day 1, n (%) | 91 (44.8) | 80 (39.6) | 171 (42.2) |
Oral daily steroid dose (prednisone equivalents) at day 1 (mg)† | 4.6 (1.97) | 4.5 (2.69) | 4.6 (2.33) |
Use of NSAIDs at day 1, n (%) | 172 (84.7) | 167 (82.7) | 339 (83.7) |
Values are mean (SD) unless otherwise specified.
*Total (n=405), abatacept+MTX (n=203), placebo+MTX (n=202).
†Total (n=171), abatacept+MTX (n=91), placebo+MTX (n=80).
CRP, C-reactive protein; DAS28, Disease Activity Score 28; HAQ-DI, Health Assessment Questionnaire-Disability Index; JSN, joint-space narrowing; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug; RA, rheumatoid arthritis; TSS, total Sharp score.